BR0210510A - Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo - Google Patents
Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmoInfo
- Publication number
- BR0210510A BR0210510A BR0210510-1A BR0210510A BR0210510A BR 0210510 A BR0210510 A BR 0210510A BR 0210510 A BR0210510 A BR 0210510A BR 0210510 A BR0210510 A BR 0210510A
- Authority
- BR
- Brazil
- Prior art keywords
- group
- lower alkyl
- alkoxy
- nitrogen
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"DERIVADO HETEROCìCLICO CONTENDO NITROGêNIO, COMPOSIçãO MEDICINAL CONTENDO O MESMO, USO MéDICO DO MESMO E INTERMEDIáRIO PARA O MESMO". A presente invenção propõe derivados heterocíclicos contendo nitrogênio representados pela fórmula geral: em que X^ 1^ e X^ 3^ representam independentemente N ou CH; X^ 2^ representa N ou CR^ 2^; X^ 4^ representa N ou CR^ 3^; e desde que um ou dois dos X^ l^, X^ 2^, X^ 3^ e X^ 4^ representem N; R^ 1^ representa um átomo de hidrogênio, um átomo de halogênio, um grupamento alquila inferior, um grupamento alcóxi inferior, um grupamento alquiltio inferior, um grupamento (alquila inferior) substituído por alcóxi inferior, um grupamento (alcóxi inferior) substituido por alcóxi inferior, um grupamento (alquila inferior) substituído por um (alcóxi inferior substituído por alcóxi inferior), um grupamento cíclico alquila inferior, um grupamento halo (alquila inferior) ou um grupamento representado pela fórmula geral: HO-A- em que A representa um grupamento alquileno inferior, um grupamento alquilenóxi inferior ou um grupamento alquileno-tio inferior; R^ 2^ representa um átomo de hidrogênio, um átomo de halogênio, um grupamento alquila inferior, um grupamento alquila inferior cíclico, um grupamento alcóxi inferior, um grupamento amino, um grupamento (acil inferior)amino , um grupamento mono(alquil inferior)amino ou um grupamento di(alquil inferior)amino; e R^ 3^ representa um átomo de hidrogênio ou um grupamento alquila inferior, ou sais seus aceitáveis do ponto de vista farmacêutico, ou promedicamentos seus, que são úteis como agentes para a prevenção ou tratamento de uma doença associada com hiperglicemia tal como diabetes, complicações diabéticas ou obesidade, composições farmacêuticas compreendendo os mesmos, e empregos farmacêuticos e produção de intermediários para os mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001187368 | 2001-06-20 | ||
PCT/JP2002/006000 WO2003000712A1 (fr) | 2001-06-20 | 2002-06-17 | Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0210510A true BR0210510A (pt) | 2005-01-11 |
Family
ID=19026665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0210510-1A BR0210510A (pt) | 2001-06-20 | 2002-06-17 | Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo |
Country Status (9)
Country | Link |
---|---|
US (1) | US7271153B2 (pt) |
EP (1) | EP1405859A4 (pt) |
JP (1) | JP4399254B2 (pt) |
KR (1) | KR100882179B1 (pt) |
CN (1) | CN100376592C (pt) |
BR (1) | BR0210510A (pt) |
CA (1) | CA2455300A1 (pt) |
HK (1) | HK1068895A1 (pt) |
WO (1) | WO2003000712A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
JP4399254B2 (ja) * | 2001-06-20 | 2010-01-13 | キッセイ薬品工業株式会社 | 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体 |
CA2478889A1 (en) | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co., Ltd. | Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
WO2004058790A1 (ja) * | 2002-12-25 | 2004-07-15 | Kissei Pharmaceutical Co., Ltd. | 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
US7439232B2 (en) | 2003-04-01 | 2008-10-21 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
AU2003902263A0 (en) * | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
CA2549025A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indole-o-glucosides |
CA2549022A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides |
WO2005012318A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica Nv | Substituted fused heterocyclic c-glycosides |
RS20060320A (en) | 2003-08-01 | 2008-08-07 | Janssen Pharmaceutica N.V., | Substituted indazole-o-glucosides |
SI1651658T2 (sl) | 2003-08-01 | 2020-12-31 | Mitsubishi Tanabe Pharma Corporation | Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija |
WO2005085265A1 (ja) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途 |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
CA2579716A1 (en) * | 2004-06-23 | 2006-01-05 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists |
US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
UA105480C2 (uk) | 2007-09-10 | 2014-05-26 | Янссен Фармацевтика Н.В. | Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
PE20110288A1 (es) * | 2008-08-28 | 2011-05-26 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
ES2416459T3 (es) | 2009-07-10 | 2013-08-01 | Janssen Pharmaceutica, N.V. | Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno |
DK2488515T3 (en) * | 2009-10-14 | 2017-02-27 | Janssen Pharmaceutica Nv | PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2 |
NZ599945A (en) | 2009-11-02 | 2014-05-30 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
WO2011070592A2 (en) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Novel sugar derivatives |
ES2596291T3 (es) | 2010-05-11 | 2017-01-05 | Janssen Pharmaceutica, N.V. | Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt |
PT2697218T (pt) | 2011-04-13 | 2016-07-13 | Janssen Pharmaceutica Nv | Processo para preparação de compostos úteis como inibidores da sglt2 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
CN103308670B (zh) * | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
BR112015022441B1 (pt) | 2013-03-14 | 2021-12-07 | Mars, Incorporated | Composição de sabor que contém glicosídeos de hmg |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
CN110678463B (zh) | 2017-06-01 | 2023-06-06 | 百时美施贵宝公司 | 经取代的含氮化合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK149818C (da) | 1976-10-28 | 1987-04-06 | Sankyo Co | Analogifremgangsmaade til fremstilling af 5-fluoruracil-derivater |
JPS53135987A (en) | 1977-04-15 | 1978-11-28 | Sankyo Co Ltd | 5-fluorouracil derivative |
JPS53144582A (en) | 1977-05-20 | 1978-12-15 | Sankyo Co Ltd | 5-fluorouracil derivatives |
US4248999A (en) * | 1976-10-28 | 1981-02-03 | Sankyo Company Limited | 5-Fluorouracil derivatives and process for preparing thereof |
JP3994461B2 (ja) * | 1996-12-27 | 2007-10-17 | 和光純薬工業株式会社 | ヒドロキシアルキルピリジン誘導体 |
JP2000044589A (ja) * | 1998-08-03 | 2000-02-15 | Kikkoman Corp | マルトオリゴ糖誘導体及びその用途 |
RU2232767C2 (ru) * | 1999-08-31 | 2004-07-20 | Киссеи Фармасьютикал Ко., Лтд. | Глюкопиранозилоксипиразольные производные, фармацевтические композиции, содержащие эти производные, и промежуточные соединения для их получения |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
JP4399254B2 (ja) * | 2001-06-20 | 2010-01-13 | キッセイ薬品工業株式会社 | 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体 |
-
2002
- 2002-06-17 JP JP2003507115A patent/JP4399254B2/ja not_active Expired - Fee Related
- 2002-06-17 CN CNB028149750A patent/CN100376592C/zh not_active Expired - Fee Related
- 2002-06-17 US US10/481,013 patent/US7271153B2/en not_active Expired - Fee Related
- 2002-06-17 CA CA002455300A patent/CA2455300A1/en not_active Abandoned
- 2002-06-17 KR KR1020037016444A patent/KR100882179B1/ko not_active IP Right Cessation
- 2002-06-17 EP EP02738729A patent/EP1405859A4/en not_active Withdrawn
- 2002-06-17 WO PCT/JP2002/006000 patent/WO2003000712A1/ja active Application Filing
- 2002-06-17 BR BR0210510-1A patent/BR0210510A/pt not_active IP Right Cessation
-
2005
- 2005-02-18 HK HK05101369A patent/HK1068895A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2003000712A1 (fr) | 2003-01-03 |
CN100376592C (zh) | 2008-03-26 |
CA2455300A1 (en) | 2003-01-03 |
JPWO2003000712A1 (ja) | 2005-04-21 |
CN1537114A (zh) | 2004-10-13 |
KR20040010723A (ko) | 2004-01-31 |
US7271153B2 (en) | 2007-09-18 |
KR100882179B1 (ko) | 2009-02-06 |
US20050049203A1 (en) | 2005-03-03 |
EP1405859A1 (en) | 2004-04-07 |
HK1068895A1 (en) | 2005-05-06 |
JP4399254B2 (ja) | 2010-01-13 |
EP1405859A4 (en) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0210510A (pt) | Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo | |
NO20020968L (no) | Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav | |
EP1609798A4 (en) | CONDENSED HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, AND MEDICAL USE THEREOF | |
NO20051209L (no) | Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme | |
NO20064412L (no) | Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav | |
BR0312999A (pt) | Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente | |
BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
BR0307576A (pt) | Compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças associadas com o dpp iv; e uso de compostos | |
BRPI0508243A (pt) | derivados de anéis fundidos nitrogenados, composições medicinais contendo os derivados e uso destas como drogas | |
BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
TW200637869A (en) | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same | |
BR0314383A (pt) | Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf) | |
BRPI0417458A (pt) | compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento | |
BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
BR0212069A (pt) | Agentes antidiabéticos orais | |
MXPA05011176A (es) | Derivados de carboxamida como agentes antidiabeticos. | |
BR0308765A (pt) | Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7 | |
BR0206552A (pt) | Utilização de pelo menos uma quinoleìna, quinoleìna, e, composição farmacêutica | |
BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
BR0214937A (pt) | Processo de preparação de derivados de equinocandina | |
BR0315106A (pt) | Derivados antimicrobianos de [3.1.0]oxazolidinona bicìclica | |
BR0312176A (pt) | Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario | |
BR0318533A (pt) | azolidinacarbonitrilas e seu uso como inibidores de dpp-iv | |
BRPI0409217A (pt) | derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |